Ország: Egyesült Államok
Nyelv: angol
Forrás: NLM (National Library of Medicine)
IPRATROPIUM BROMIDE (UNII: J697UZ2A9J) (IPRATROPIUM - UNII:GR88G0I6UL)
Sun Pharmaceutical Industries, Inc.
RESPIRATORY (INHALATION)
PRESCRIPTION DRUG
Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. Ipratropium Bromide (IH-pruh-TROE-pee-uhm BROE-mide) Inhalation Solution, USP 0.02% Read complete instructions carefully before using. 1. Remove vial from the foil pouch. 2. Twist open the top of one unit dose vial and squeeze the contents into the nebulizer reservoir (Figure 1). 3. Connect the nebulizer reservoir to the mouthpiece or face mask (Figure 2). 4. Connect the nebulizer to the compressor. 5. Sit in a comfortable, upright position; place the mouthpiece in your mouth (Figure 3) or put on the face mask and turn on the compressor. If a face mask is used, ca
Ipratropium Bromide Inhalation Solution, USP is a clear, colorless solution supplied in a unit-dose vial containing 2.5 mL. Supplied in cartons as listed below: NDC 47335-706-49 carton of 25 vials (5 vials per foil pouch) NDC 47335-706-52 carton of 30 vials (5 vials per foil pouch) NDC 47335-706-54 carton of 60 vials (5 vials per foil pouch) Each vial is made from a low density polyethylene (LDPE) resin. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Protect from light. Store in pouch until time of use. Dispense with Patient's Instructions For Use available at: https://www.sunpharma.com/usa/products
Abbreviated New Drug Application
IPRATROPIUM BROMIDE - IPRATROPIUM BROMIDE SOLUTION SUN PHARMACEUTICAL INDUSTRIES, INC. ---------- IPRATROPIUM BROMIDE INHALATION SOLUTION, USP 0.02% RX ONLY PRESCRIBING INFORMATION FOR INHALATION USE ONLY–NOT FOR INJECTION. DESCRIPTION The active ingredient in Ipratropium Bromide Inhalation Solution, USP is ipratropium bromide monohydrate, USP. It is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo[3.2.1]-octane,3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1- methylethyl)-, bromide, monohydrate (endo, syn)-,(±)-; a synthetic quaternary ammonium compound, chemically related to atropine. Ipratropium bromide is a white crystalline substance, freely soluble in water and lower alcohols. It is a quaternary ammonium compound and thus exists in an ionized state in aqueous solutions. It is relatively insoluble in non-polar media. Ipratropium Bromide Inhalation Solution, USP is administered by oral inhalation with the aid of a nebulizer. Each mL contains ipratropium bromide, USP 0.02% (anhydrous basis) in a sterile, preservative-free, isotonic saline solution, pH adjusted to 3.4 (3 to 4) with hydrochloric acid. CLINICAL PHARMACOLOGY Ipratropium Bromide Inhalation Solution is an anticholinergic (parasympatholytic) agent that, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increases in intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) which are caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. The bronchodilation following inhalation of Ipratropium Bromide Inhalation Solution is primarily a local, site-specific effect, not a systemic one. Much of an administered dose is swallowed but not absorbed as shown by fecal excretion studies. Following nebulization of a 2 mg dose, a mean 7% of the dose was absorbed into the systemic circulation either from the surface of the lung or from Olvassa el a teljes dokumentumot